Meeting
2018 Gastrointestinal Cancers Symposium
ISO-CC-005: A phase I/II study of Modufolin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer.
Authors
Helena Anna Taflin
Sahlgrenska University Hospital, Gothenburg, Sweden
Helena Anna Taflin , Karin M E Ganlov , Tormod Kyrre Guren , Christos Papadimitrou , Nikolaos K. Kentepozidis , Johan Haux , Per Pfeiffer , Goran Ulf Carlsson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02244632
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 838)
DOI
10.1200/JCO.2018.36.4_suppl.838
Abstract #
838
Poster Bd #
N14
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).
First Author: Stefan Kasper
Poster
2018 Gastrointestinal Cancers Symposium
Current Status of mCRC in East Europe and Middle East.
First Author: Ozan Yazici
Poster
2016 Gastrointestinal Cancers Symposium
A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC).
First Author: Andrew Dean
Poster
2015 Gastrointestinal Cancers Symposium
PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer—A GERCOR Study.
First Author: Benoist Chibaudel